Latest project updates
Oncode Institute aims to outsmart cancer and impact lives. To achieve this, Oncode focuses on three pillars: excellent research, intensive collaboration and powerful valorization. The research strategy is focused on understanding the basic mechanisms of cancer to realize the ultimate goal: safer and more effective medical solutions as well as personalized precision diagnostics. Oncode brings together excellent cancer researchers in The Netherlands: 61 research groups from 12 different Dutch research institutes collaborate on 6 interdisciplinary research themes. To speed up the translation of scientific discoveries into clinical applications, Oncode has a dedicated team of specialists to support scientists in the valorization process.
12 partner institutions
61 Principal Investigators
€ 120 million
funding for 5 years
About Oncode Institute
Over the past decades, the scientific and medical community has made tremendous progress in understanding and treating cancer. However, the disease still has a large burden on society as cancer has become the primary cause of death in The Netherlands. In an effort to address this unmet clinical need, Dutch cancer researchers have joined forces within Oncode Institute. To come up with new avenues for treatment and diagnosis, Oncode focuses on better understanding the fundamental mechanisms of cancer biology. With the ultimate goal to improve long-term survival and the quality of life of patients.Oncode serves as a platform for excellent cancer researchers in The Netherlands to collaborate, share knowledge, expertise and technology. As a virtual Institute it stimulates scientific freedom and offers dedicated support to optimize the translation of fundamental insights into clinical applications. Outsmarting cancer, impacting lives. Visit the Oncode website for more information about the project.
Over 800+ Oncode researchers working under a single strategy that focuses on six different research themes:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilising immune defence
Oncode invests heavily in the transfer of results from fundamental research into clinical applications. A team of dedicated specialists will help Oncode researchers with valorization of their findings. Furthermore, Oncode offers tailored training programs for affiliated researchers and actively invests in diversity through its Young Female Investigator program.
Accelerating innovation by partnership management
Based on its broad experience with partnership management and communication, Lygature has become a partner of Oncode. Lygature supports Oncode Institute with the following services:
- Program management
- Communication & external affairs
- Finance & IT-infrastructure
- Patient engagement
Lygature together with
Project updates
-
Oncode Scientific Director Geert Kops to leave Oncode Institute as of 1st of September
Geert Kops, Scientific Director and Head of Oncode Institute, will be leaving his leading managerial position within the institute to become the Director of the Hubrecht Institute as of 1st of September, 2023. Kops is also an Oncode Investigator, a role he will maintain. Together with his lab, he will continue to be part of the Oncode community. The recruitment procedure for a successor will start soon.
-
Harnessing Organoids to Tailor Treatments and Uncover New Therapies for Head and Neck Cancer Patients
Researchers at the Hubrecht Institute have made significant advancements in head and neck cancer treatment options by utilizing patient-derived organoids. These organoids have shown potential in predicting patient response to radiotherapy and can help identify or validate new treatment options. The Oncode Clinical Proof of Concept Grant enabled the researchers to create a diverse biobank of head and neck organoids where they could really investigate the potential of organoids to predict response to radiotherapy and genetically manipulate the organoids to explore the potential of genetic biomarker prediction using targeting therapies. This adds to the growing field of organoids, with the potential to one day impact clinical decision making.
-
Oncode Institute Calls for Aspiring Junior Investigators in Oncology Research - Apply Now!
Oncode Institute announced an open call for applications to a Junior Oncode Investigator (jr OI) position, starting on January 1st, 2024. Oncode Institute is eager to give (future) junior group leaders the opportunity to become part of the Oncode community and to gain access to support and tools to significantly contribute to oncology research. The jr OI position is an excellent opportunity for researchers looking to make an impact in oncology research, benefit from extensive support and funding, and engage with a vibrant research community. Interested candidates should submit their applications to Oncode Institute by June 14th, 2023.